Next Generation Bio banking
Biorepositories provide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standard bio banking practices and characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at the Lung Tissue Research Consortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients.
- Ownership, Property Rights and Commercialization in Relation to Biobanking
- Ethical considerations surrounding biobanking and biorepository operation.
- Legal and Ethical Framework For Collaborative Biobanking Across Europe
- Factors Influencing Biobanks Prices
- Ethical issues & future use of samples
Related Conference of Next Generation Bio banking
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
17th International Conference on Human Genetics and Genetic Diseases
Next Generation Bio banking Conference Speakers
Recommended Sessions
- Bio bank Ethics
- Bio-banks
- Cells & Organ Regeneration
- Epigenetics
- Fertility bio banks
- Next Generation Bio banking
- Stem cells apoptosis and signal transduction
- Stem cells Biomarkers
- Stem Cells Technology
- Biorepository & Biospecimen
- Cell Signalling in Development
- Stem cell Bioinformatics
- Stem Cell Embryology
- Stem Cell Niches
- Stem Cell Therapy
- Stem Cell Transplantation
- Stem Cell treatment
- Stem Cells
- Stem Cells Biology
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)

